Skip to search formSkip to main contentSkip to account menu

Antibody-Drug Conjugate SC16LD6.5

Known as: Anti-SC16 ADC SC16LD6.5, SC16LD6.5 
An antibody-drug conjugate (ADC) containing an antibody directed against the scr-like kinase Fyn3 (SC-16), conjugated to the cytotoxic agent D6.5… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
DLL3 is overexpressed in neuroendocrine prostate cancer and is a potential therapeutic target. Lessons from one tumor help with… 
Review
2019
Review
2019
BackgroundSmall-cell lung cancer (SCLC) is an aggressive disease with still limited therapeutic options. Despite being both a… 
Highly Cited
2017
Highly Cited
2017
The Notch ligand DLL3 has emerged as a novel therapeutic target expressed in small cell lung cancer (SCLC) and high-grade… 
2017
2017
Expression of DLL3 was examined in additional tumor types, as it was found to be highly expressed in tumor-initiating cells (TIC… 
2016
2016
LBA8505Background: SCLC remains among the most deadly of malignancies. Rovalpituzumab tesirine is a first-in-class ADC comprised… 
2016
2016
  • S. Dylla
  • Molecular & cellular oncology
  • 2016
  • Corpus ID: 41908753
ABSTRACT Delta-like protein 3 (DLL3) is a novel and tractable tumor-initiating cell-associated target for the antibody-drug… 
2016
2016
Highly Cited
2015
Highly Cited
2015
Targeting DLL3 with an antibody-drug conjugate eliminates tumor-initiating cells in high-grade pulmonary neuroendocrine cancers… 
2003
2003
An in situ study of the kinetics of relaxation of the gamma-gamma' lattice mismatch in the single-crystal Ni-base superalloy SC16… 
Highly Cited
1995
Highly Cited
1995
A first-principles pseudopotential study of the phase stability of the III-V semiconductors GaAs and AlAs is reported. For both…